Oxford Covid-19 vaccine showing strong immune response in older people

Henrietta Strickland
November 20, 2020

Recruit diverse populations to participate in clinical trials for a COVID-19 vaccine to ensure the data reflect the racial, ethnic, age and gender diversity of the US.

Phase 3 results have already been published by rival vaccine makers Pfizer/BioNtech and Moderna, both of which showed around 95 per cent effectiveness. "The Phase 2 interim data for AZD122 suggests that individuals have lower reactogenicity whilst still maintaining a robust immune response", said Mene Pangalos, Executive Vice President of BioPharmaceuticals Research and Development.

"Up until now, we've looked at antibody, which protects the circulating fluid (blood and tissue flow) from the virus".

That will include people in high-risk jobs, such as the health workforce, older people, disabled people, Māori and Pasifika, and people with multiple health problems.

Last week, the government approved spending $48 million to buy 4 million doses of a vaccine being developed by USA drugmaker Pfizer Inc and its partner BioNTech of Germany.

The data from the Oxford-AstraZeneca Phase 2 trial comes as two USA -based pharmaceutical companies report their COVID-19 vaccines are more than 90% effective against the virus. The SinoPharm vaccine, meanwhile, has been undergoing Phase-3 trials in the United Arab Emirates, with Prime Minister Sheikh Mohammed bin Rashid Al Maktoum reportedly receiving a dose of it on November 3.

The results from an early phased randomised clinical trial of a Chinese vaccine for COVID-19 has proven to be safe and induces an antibody response in health volunteers aged 18 to 59 years. Participants aged over 55 years were also split into groups and either given a single dose of vaccine, or two doses 28 days apart. They began during a national lockdown in the U.K.so it wasn't possible to recruit volunteers from the most vulnerable groups.

Another excellent piece of news is that the vaccine is well tolerated with side effects only around the injection site and only lasting for a short period of time.

He said Butantan expects to have 46 million doses ready in January pending approval of the vaccine by Brazil's health regulator Anvisa.

The trial included 560 participants ages 18 and older, of which 209 received a boost dose. Researchers believe the immune response they found would provide protection.

Older adults have an increased risk of COVID-19, so it's crucial that vaccines against the disease are effective in this age group.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER